Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MB-CART19.1 |
Trade Name | |
Synonyms | MBCART19.1|MB CART19.1|Autologous CD19 CAR-expressing CD4/CD8 pos T-cells |
Drug Descriptions |
MB-CART19.1 consists of CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing 4-1-BBz, which potentially inhibits tumor growth (Blood (2021) 138 (Supplement 1): 3836; NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C172103 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MB-CART19.1 | MB-CART19.1 | 0 | 2 |